329 related articles for article (PubMed ID: 31296171)
1. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
2. Switching of anti-TNF-α agents in Behçet's disease.
Furuta S; Chow YW; Chaudhry AN; Jayne D
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
Bektaş M; Özer MD; Oğuz E
Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
[TBL] [Abstract][Full Text] [Related]
4. Paediatric Behçet's disease: a UK tertiary centre experience.
Nanthapisal S; Klein NJ; Ambrose N; Eleftheriou D; Brogan PA
Clin Rheumatol; 2016 Oct; 35(10):2509-16. PubMed ID: 26833394
[TBL] [Abstract][Full Text] [Related]
5. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
[TBL] [Abstract][Full Text] [Related]
6. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
[TBL] [Abstract][Full Text] [Related]
7. [Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy].
Kaneko U; Kishi T; Kikuchi M; Hara R; Shinoki T; Miyamae T; Imagawa T; Mori M; Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(3):157-61. PubMed ID: 20601837
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
9. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.
Aikawa NE; Gonçalves C; Silva CA; Gonçalves C; Bonfá E; de Carvalho JF
Rheumatol Int; 2011 Aug; 31(8):1097-9. PubMed ID: 20012049
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.
Cantarini L; Tinazzi I; Caramaschi P; Bellisai F; Brogna A; Galeazzi M
Int J Immunopathol Pharmacol; 2009; 22(2):551-5. PubMed ID: 19505410
[TBL] [Abstract][Full Text] [Related]
13. Juvenile Behçet's disease among 1784 Turkish Behçet's patients.
Sarica R; Azizlerli G; Köse A; Dişçi R; Ovül C; Kural Z
Int J Dermatol; 1996 Feb; 35(2):109-11. PubMed ID: 8850038
[TBL] [Abstract][Full Text] [Related]
14. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
Sfikakis PP
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
Arida A; Fragiadaki K; Giavri E; Sfikakis PP
Semin Arthritis Rheum; 2011 Aug; 41(1):61-70. PubMed ID: 21168186
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of adalimumab as an add-on therapy in two cases with leg ulcers in Behçet's disease resistant to conventional immunosuppressive therapy alone and a review of the literature.
Kaban N; Harman H
Mod Rheumatol Case Rep; 2023 Dec; 8(1):205-209. PubMed ID: 37534898
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for Behcet's syndrome.
Saenz A; Ausejo M; Shea B; Wells G; Welch V; Tugwell P
Cochrane Database Syst Rev; 2000; 1998(2):CD001084. PubMed ID: 10796413
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline for the treatment of anterior uveitis in Behcet's disease: possible alternative for TNF blockers.
Appenzeller S; Hazel E
Rheumatol Int; 2011 Nov; 31(11):1511-3. PubMed ID: 20013266
[TBL] [Abstract][Full Text] [Related]
20. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
